View ValuationCompumedics 将来の成長Future 基準チェック /56Compumedics利益と収益がそれぞれ年間43.5%と19.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に40.3% 43.6%なると予測されています。主要情報43.5%収益成長率43.58%EPS成長率Medical Equipment 収益成長13.4%収益成長率19.4%将来の株主資本利益率40.32%アナリストカバレッジLow最終更新日17 Apr 2026今後の成長に関する最新情報お知らせ • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.お知らせ • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.お知らせ • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.お知らせ • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.すべての更新を表示Recent updatesお知らせ • Jun 09Compumedics Limited Announces Appointment of Mike Stone as Chief Commercial Officer for Its US OperationsCompumedics Limited announced appointment of Mike Stone as Chief Commercial Officer for its US operations. Mike brings over 20 years of medical device commercial leadership, with a proven record of scaling sales organizations, retaining key talent through M&A transitions, and integrating acquired businesses. Since joining, he has already strengthened the U.S. team with several high-caliber hires, with additional key appointments underway. Mike is charged with two strategic priorities: building out Compumedics' US neurodiagnostics business and strengthening the sleep and IDTF commercial teams to support continued growth, including Somfit, the company's EEG-enabled home sleep testing platform. Mike joins from Baxter International, where he led commercial operations spanning alternate site distribution and pharmaceutical manufacturing channels. Prior to Baxter, he served as Vice President of Sales at Smiths Medical, managing a $500 million plus P&L and holding the commercial organization together through its acquisition by ICU Medical. Earlier in his career, Mike led post-acquisition integration and team building across multiple transactions at Henry Schein, the Fortune 250 healthcare products and distribution leader. His tenure as Vice President of Sales for Neurology at Nihon Kohden gives him direct domain experience in EEG, sleep diagnostics, and software sales, where he transformed an underperforming business and drove strong double-digit growth sustained over multiple years. Mike holds an MBA from Georgia State University and a BS from the University of South Florida. He is based in Wellington, Florida.Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Chris Barrys was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Chris Barys was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 30Compumedics Limited Elects Mr. Christopher Barys as DirectorCompumedics Limited elected Mr. Christopher Barys as director.お知らせ • Oct 15Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,543,860 Price\Range: AUD 0.285 Discount Per Security: AUD 0.0171 Transaction Features: Subsequent Direct Listingお知らせ • Oct 01Compumedics Limited, Annual General Meeting, Oct 30, 2025Compumedics Limited, Annual General Meeting, Oct 30, 2025. Location: 30-40 flockhart street, abbotsford victoria 3067, and via zoom meeting, AustraliaReported Earnings • Aug 28Full year 2025 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2024)Full year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 276% from FY 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 05Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,269,231 Price\Range: AUD 0.26 Discount Per Security: AUD 0.0156 Transaction Features: Subsequent Direct ListingReported Earnings • Oct 02Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.002 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.3m (up 17% from FY 2023). Net loss: AU$338.0k (loss narrowed 95% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.2m (up 17% from FY 2023). Net loss: AU$499.0k (loss narrowed 92% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (AU$65.3m market cap, or US$44.1m).Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 02Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.035 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 11% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.お知らせ • Sep 28Compumedics Limited, Annual General Meeting, Oct 31, 2023Compumedics Limited, Annual General Meeting, Oct 31, 2023, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street, Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the Company and the reports of the Directors and the Company's auditor for the year ended 30 June 2023; to consider the election of Director; and to consider the adoption of Remuneration Report.New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 43% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (AU$35.4m market cap, or US$23.0m).お知らせ • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.お知らせ • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.Reported Earnings • Mar 03First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022)First half 2023 results: AU$0.041 loss per share (down from AU$0.002 profit in 1H 2022). Revenue: AU$19.2m (up 14% from 1H 2022). Net loss: AU$7.21m (down AU$7.50m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.お知らせ • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.Board Change • Jan 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.Board Change • Aug 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jul 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 03First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: EPS: AU$0.002 (down from AU$0.007 in 1H 2021). Revenue: AU$16.8m (down 7.0% from 1H 2021). Net income: AU$287.0k (down 78% from 1H 2021). Profit margin: 1.7% (down from 7.3% in 1H 2021). Revenue missed analyst estimates by 4.4%. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Board Change • Jan 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Tucson Dunn was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 31Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Non-Executive Director Tucson Dunn was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 01Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$35.7m (up 1.9% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 28Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$37.3m (up 6.2% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.7% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Mar 10New 90-day low: AU$0.41The company is down 17% from its price of AU$0.49 on 08 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.Is New 90 Day High Low • Jan 13New 90-day low: AU$0.41The company is down 7.0% from its price of AU$0.45 on 16 October 2020. The Australian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$1.73 per share.業績と収益の成長予測CHIA:CMP - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202911617101216/30/2028951381016/30/20278095816/30/202666424112/31/2025580-14N/A9/30/202555-1-42N/A6/30/202551-1-70N/A3/31/202549-1-70N/A12/31/202447-2-7-1N/A9/30/202449-1-40N/A6/30/2024500-12N/A3/31/2024500-12N/A12/31/2023501-12N/A9/30/202347-2-31N/A6/30/202343-6-40N/A3/31/202342-6-31N/A12/31/202241-6-22N/A9/30/202240-2-12N/A6/30/202239103N/A3/31/202237103N/A12/31/202134002N/A9/30/202135002N/A6/30/202136101N/A3/31/202135-212N/A12/31/202035-524N/A9/30/202035-514N/A6/30/202035-615N/A3/31/202038-105N/A12/31/2019413-15N/A9/30/2019414N/A5N/A6/30/2019424N/A5N/A3/31/2019413N/A4N/A12/31/2018403N/A3N/A9/30/2018383N/A2N/A6/30/2018373N/A1N/A3/31/2018362N/A0N/A12/31/2017342N/A-1N/A9/30/2017342N/A0N/A6/30/2017341N/A1N/A3/31/2017351N/A2N/A12/31/2016362N/A4N/A9/30/2016372N/A3N/A6/30/2016383N/A2N/A3/31/2016363N/A2N/A12/31/2015353N/A1N/A9/30/2015342N/A2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CMPの予測収益成長率 (年間43.5% ) は 貯蓄率 ( 3.6% ) を上回っています。収益対市場: CMPの収益 ( 43.5% ) はAustralian市場 ( 11.4% ) よりも速いペースで成長すると予測されています。高成長収益: CMPの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: CMPの収益 ( 19.4% ) Australian市場 ( 5.9% ) よりも速いペースで成長すると予測されています。高い収益成長: CMPの収益 ( 19.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CMPの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 40.3 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/09 00:58終値2026/07/09 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Compumedics Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Ian MartinNew Street Research LLPPaul JenszPAC Partners Securities Pty. Ltd.Stephen ScottTaylor Collison Limited
お知らせ • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.
お知らせ • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.
お知らせ • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.
お知らせ • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.
お知らせ • Jun 09Compumedics Limited Announces Appointment of Mike Stone as Chief Commercial Officer for Its US OperationsCompumedics Limited announced appointment of Mike Stone as Chief Commercial Officer for its US operations. Mike brings over 20 years of medical device commercial leadership, with a proven record of scaling sales organizations, retaining key talent through M&A transitions, and integrating acquired businesses. Since joining, he has already strengthened the U.S. team with several high-caliber hires, with additional key appointments underway. Mike is charged with two strategic priorities: building out Compumedics' US neurodiagnostics business and strengthening the sleep and IDTF commercial teams to support continued growth, including Somfit, the company's EEG-enabled home sleep testing platform. Mike joins from Baxter International, where he led commercial operations spanning alternate site distribution and pharmaceutical manufacturing channels. Prior to Baxter, he served as Vice President of Sales at Smiths Medical, managing a $500 million plus P&L and holding the commercial organization together through its acquisition by ICU Medical. Earlier in his career, Mike led post-acquisition integration and team building across multiple transactions at Henry Schein, the Fortune 250 healthcare products and distribution leader. His tenure as Vice President of Sales for Neurology at Nihon Kohden gives him direct domain experience in EEG, sleep diagnostics, and software sales, where he transformed an underperforming business and drove strong double-digit growth sustained over multiple years. Mike holds an MBA from Georgia State University and a BS from the University of South Florida. He is based in Wellington, Florida.
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Chris Barrys was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.
Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Chris Barys was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 30Compumedics Limited Elects Mr. Christopher Barys as DirectorCompumedics Limited elected Mr. Christopher Barys as director.
お知らせ • Oct 15Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,543,860 Price\Range: AUD 0.285 Discount Per Security: AUD 0.0171 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 01Compumedics Limited, Annual General Meeting, Oct 30, 2025Compumedics Limited, Annual General Meeting, Oct 30, 2025. Location: 30-40 flockhart street, abbotsford victoria 3067, and via zoom meeting, Australia
Reported Earnings • Aug 28Full year 2025 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2024)Full year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 276% from FY 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 05Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,269,231 Price\Range: AUD 0.26 Discount Per Security: AUD 0.0156 Transaction Features: Subsequent Direct Listing
Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.002 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.3m (up 17% from FY 2023). Net loss: AU$338.0k (loss narrowed 95% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.2m (up 17% from FY 2023). Net loss: AU$499.0k (loss narrowed 92% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (AU$65.3m market cap, or US$44.1m).
Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 02Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.035 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 11% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
お知らせ • Sep 28Compumedics Limited, Annual General Meeting, Oct 31, 2023Compumedics Limited, Annual General Meeting, Oct 31, 2023, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street, Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the Company and the reports of the Directors and the Company's auditor for the year ended 30 June 2023; to consider the election of Director; and to consider the adoption of Remuneration Report.
New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 43% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (AU$35.4m market cap, or US$23.0m).
お知らせ • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.
お知らせ • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.
Reported Earnings • Mar 03First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022)First half 2023 results: AU$0.041 loss per share (down from AU$0.002 profit in 1H 2022). Revenue: AU$19.2m (up 14% from 1H 2022). Net loss: AU$7.21m (down AU$7.50m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.
お知らせ • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.
Board Change • Jan 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.
Board Change • Aug 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jul 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 03First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: EPS: AU$0.002 (down from AU$0.007 in 1H 2021). Revenue: AU$16.8m (down 7.0% from 1H 2021). Net income: AU$287.0k (down 78% from 1H 2021). Profit margin: 1.7% (down from 7.3% in 1H 2021). Revenue missed analyst estimates by 4.4%. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Board Change • Jan 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Tucson Dunn was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 31Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Non-Executive Director Tucson Dunn was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 01Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$35.7m (up 1.9% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 28Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$37.3m (up 6.2% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.7% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Mar 10New 90-day low: AU$0.41The company is down 17% from its price of AU$0.49 on 08 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.
Is New 90 Day High Low • Jan 13New 90-day low: AU$0.41The company is down 7.0% from its price of AU$0.45 on 16 October 2020. The Australian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$1.73 per share.